中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2010年
9期
541-545
,共5页
应灵军%郑临%吕国才%徐陈槐%吴炜%杨益大
應靈軍%鄭臨%呂國纔%徐陳槐%吳煒%楊益大
응령군%정림%려국재%서진괴%오위%양익대
CD8阳性T淋巴细胞%白细胞介素7受体α亚单位%聚乙烯二醇类%干扰素α-2a%肝炎,乙型,慢性%肝炎e抗原,乙型%基因表达
CD8暘性T淋巴細胞%白細胞介素7受體α亞單位%聚乙烯二醇類%榦擾素α-2a%肝炎,乙型,慢性%肝炎e抗原,乙型%基因錶達
CD8양성T림파세포%백세포개소7수체α아단위%취을희이순류%간우소α-2a%간염,을형,만성%간염e항원,을형%기인표체
CD8-positive T lymphocytes%Interleukin-7 receptor alpha subunit%Polyethylene glycols%Interferon alfa-2a%Hepatitis B,chronic%Hepatitis B e antigens%Gene expression
目的 观察聚乙二醇干扰索α-2a抗病毒治疗对HBeAg阳性慢性乙型肝炎患者记忆性CD8+T淋巴细胞CD127分子表达的影响.方法 30例HBeAg阳性慢性乙型肝炎患者接受聚乙二醇干扰素α-2a治疗,每周1次,共48周.根据CD45RA、CD27分子表达来判定记忆性CD8+T淋巴细胞,以流式细胞术检测CD127在CD8+T淋巴细胞上的表达.组间均数比较采用Mann-Whitney检验.结果 HBeAg阳性慢性乙型肝炎患者在CD45RA-CD27+记忆性CD8+T淋巴细胞上CD127的表达较健康对照组明显降低(Z=2.889,P＜0.05),其表达水平与血清HBV DNA水平和HBeAg呈负相关.聚乙二醇干扰素α-2a抗病毒治疗应答较佳者随着HBV DNA和HBeAg水平的下降,记忆性CD8+T淋巴细胞表面CD127分子的表达在治疗24、48和72周都明显增加,而应答欠佳者则无明显变化(Z24周=1.954,Z48周=2.789,Z72周=2.989;均P＜0.05).结论 慢性乙型肝炎患者通过有效的抗病毒治疗,CD8+T淋巴细胞表达CD127增加,CD127在记忆性CD8+T淋巴细胞上的表达水平可作为判定抗病毒治疗有效的重要标志.
目的 觀察聚乙二醇榦擾索α-2a抗病毒治療對HBeAg暘性慢性乙型肝炎患者記憶性CD8+T淋巴細胞CD127分子錶達的影響.方法 30例HBeAg暘性慢性乙型肝炎患者接受聚乙二醇榦擾素α-2a治療,每週1次,共48週.根據CD45RA、CD27分子錶達來判定記憶性CD8+T淋巴細胞,以流式細胞術檢測CD127在CD8+T淋巴細胞上的錶達.組間均數比較採用Mann-Whitney檢驗.結果 HBeAg暘性慢性乙型肝炎患者在CD45RA-CD27+記憶性CD8+T淋巴細胞上CD127的錶達較健康對照組明顯降低(Z=2.889,P＜0.05),其錶達水平與血清HBV DNA水平和HBeAg呈負相關.聚乙二醇榦擾素α-2a抗病毒治療應答較佳者隨著HBV DNA和HBeAg水平的下降,記憶性CD8+T淋巴細胞錶麵CD127分子的錶達在治療24、48和72週都明顯增加,而應答欠佳者則無明顯變化(Z24週=1.954,Z48週=2.789,Z72週=2.989;均P＜0.05).結論 慢性乙型肝炎患者通過有效的抗病毒治療,CD8+T淋巴細胞錶達CD127增加,CD127在記憶性CD8+T淋巴細胞上的錶達水平可作為判定抗病毒治療有效的重要標誌.
목적 관찰취을이순간우색α-2a항병독치료대HBeAg양성만성을형간염환자기억성CD8+T림파세포CD127분자표체적영향.방법 30례HBeAg양성만성을형간염환자접수취을이순간우소α-2a치료,매주1차,공48주.근거CD45RA、CD27분자표체래판정기억성CD8+T림파세포,이류식세포술검측CD127재CD8+T림파세포상적표체.조간균수비교채용Mann-Whitney검험.결과 HBeAg양성만성을형간염환자재CD45RA-CD27+기억성CD8+T림파세포상CD127적표체교건강대조조명현강저(Z=2.889,P＜0.05),기표체수평여혈청HBV DNA수평화HBeAg정부상관.취을이순간우소α-2a항병독치료응답교가자수착HBV DNA화HBeAg수평적하강,기억성CD8+T림파세포표면CD127분자적표체재치료24、48화72주도명현증가,이응답흠가자칙무명현변화(Z24주=1.954,Z48주=2.789,Z72주=2.989;균P＜0.05).결론 만성을형간염환자통과유효적항병독치료,CD8+T림파세포표체CD127증가,CD127재기억성CD8+T림파세포상적표체수평가작위판정항병독치료유효적중요표지.
Objective To analyze CD127 expression on the memory CD8+ lymphocytes from hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients treated with peginterferon α-2a (Pegasys). Methods Thirty HBeAg positive CHB patients were treated with peginterferon α-2a 180 μg once a week for 48 weeks and followed up for 24 weeks. The memory CD8+ lymphocytes were characterized by expressing CD45RA and CD27 markers. CD127 expression on cell surface was measured by four-colour flow cytometry. The difference of mean values between groups was evaluated by Mann-Whitney test. Results The CD127 expression on CD8+ T lymphocytes was significantly lower in HBeAg positive CHB patients compared to healthy controls (Z=2.889, P＜0.05), which was negatively correlated with serum hepatitis B virus (HBV) DNA level and HBeAg titers. The CD127 expression increased along with the decrease of HBV DNA and HBeAg after 24-week, 48-week and 72-week treatment in patients showing good response to peginterferon α-2a, while CD127 expression didn't change markedly in non responders (Z24w = 1.954, Z48w = 2.789, Z72w = 2. 989; all P＜0. 05). Conclusion CD127 expression on memory CD8+ lymphocytes increases along with effective anti-HBV treatment in CHB patients, which can be used as a marker for evaluating the effectiveness of anti-viral treatment.
